Toronto, December 13, 2018 – Neil Grubert and MORSE Consulting are pleased to announce the release of a new report entitled Pharmaceutical Managed Entry Agreements – Lessons Learned from Europe, the United States, Canada, and Australia.
A performance or outcomes-based agreement (OBA) tracks the effectiveness of a drug in a defined patient population over a specified period of time and directly links the price or reimbursement of the product to the clinical or economic outcomes achieved. This report is a comprehensive literature review and assessment of the current trends, challenges, and opportunities in key international markets with a focus on providing clarity on the feasibility of such innovative OBAs. Based on the results of this analysis, a series of key questions was developed for payers and manufacturers to consider when laying the groundwork for an OBA.
The report covers payer reimbursement environments in the following 10 global markets:
- Australia
- Canada
- France
- Germany
- Italy
- Netherlands
- Spain
- Sweden
- United Kingdom
- United States
The use of pharmaceutical managed entry agreements has become virtually ubiquitous in key global markets. While financially based agreements are the norm, the growing number of high-priced specialty drugs for niche populations often requires more nuanced solutions. With healthcare systems around the world facing sustainability issues, payers are now giving serious consideration to the use of OBAs to facilitate access while mitigating financial risk. This report is a timely and comprehensive review of the current international environment and poses important questions that need to be asked by payers and companies when contemplating the implementation of OBAs.
A complimentary copy of this report can be downloaded here.
About the Authors:
Neil Grubert is a UK-based independent global market access consultant with 29 years of experience tracking the global prescription drug and self-medication markets. He has written more than 150 reports on all aspects of pricing, reimbursement, and market access in 20 mature and emerging markets and across multiple therapeutic areas.
MORSE Consulting Inc. is a leader in strategic pharmaceutical market access consulting in Canada. Our team has significant expertise in reimbursement strategy in a wide range of therapeutic areas and has built a reputation for providing meaningful strategic insights. MORSE has established strong, constructive relationships with healthcare stakeholders and a proven track record for delivering impactful results to its clients.
